Summary:
Phase 2/3, 24 week, study comparing the efficcy and safety of PT001 to placebo and open-label Spiriva Respimat in subjects with persistent Asthma.
Qualified Participants Must:
• Have persistent Asthma
•
Be 12-80 years old
•
Have no other lung or breathing issues, not smoked in the last 6 months
Qualified Participants May Receive:
Study medication for Ashtma, study supplies, study exams and compensation for time and travel.